DSIP vs Selank
Neuropeptide · Anxiolytic Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
DSIP
Promotes delta-wave sleep and reduces cortisol; the body produces it naturally, but its mechanism remains incompletely understood after nearly 50 years of research.
Selank
Reduces anxiety without sedation or dependence; a tuftsin-derived peptide with clear GABAergic mechanism and Russian regulatory approval.
DSIP
518 studies
17 human trials
Not FDA-Approved
Selank
88 studies
6 human trials
Not FDA-Approved
What it does
DSIP
Promotes delta-wave sleep (the deepest stage of sleep) and reduces cortisol-driven stress responses. First isolated from rabbit brain in 1977. The body produces DSIP naturally, but the molecular mechanism of action remains incompletely understood after nearly 50 years of research.
Selank
Reduces anxiety without causing sedation, cognitive impairment, or dependence. Modulates the GABA system and enkephalin pathways to calm the stress response while preserving mental clarity.
How it works
DSIP
DSIP acts on the hypothalamus to promote delta-wave (slow-wave) sleep, the stage associated with the deepest physical restoration. Published research documents effects on cortisol reduction, modulation of the hypothalamic-pituitary-adrenal (HPA) axis, and influence on circadian rhythm regulation. Despite these observed effects, the specific receptor target and signal transduction pathway for DSIP have not been definitively identified. The peptide appears to function as a neuromodulator rather than through a single receptor-mediated pathway.
Selank
Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. It modulates GABAergic signaling (the brain's primary inhibitory system), increases enkephalin activity (the body's own anxiety-reducing peptides), and influences serotonin metabolism. Unlike benzodiazepines, which also target GABA but cause sedation and dependence, Selank achieves anxiolytic effects without those liabilities. It also increases BDNF expression, a growth factor that supports synaptic plasticity and cognitive function.
How often
DSIP
In published research, DSIP has been administered intravenously and intranasally in human studies. The compound is available through research peptide markets. No FDA-approved product exists. No standardized clinical dosing protocol has been established.
Selank
In Russian clinical practice, Selank is administered as a nasal spray. The compound received Russian regulatory approval for anxiolytic use. No FDA-approved product exists. Research protocols outside Russia primarily use nasal administration.
How strong
DSIP
Multiple human studies document sleep-promoting and stress-reducing effects, primarily from European research groups in the 1980s and 1990s. The compound has also been studied for opioid withdrawal and chronic pain management. The endogenous origin (the body naturally produces DSIP) provides biological plausibility. However, the incomplete mechanistic understanding limits the ability to predict effects, optimize dosing, or assess long-term safety.
Selank
Anxiolytic effects documented in Russian human clinical studies with regulatory approval. The absence of sedation, cognitive impairment, and dependence liability distinguishes Selank from conventional anxiolytics. BDNF elevation provides a secondary cognitive support mechanism. The compound has both anxiolytic and nootropic properties in published research.
Main tradeoff
DSIP
Observed effects across multiple human studies but without a clear mechanistic explanation. The body naturally produces DSIP, which provides safety plausibility, but the incomplete understanding of how it works means the compound cannot be optimized, dose-targeted, or safety-profiled with the precision that a well-characterized mechanism would allow. Most published research is from the 1980s and 1990s with limited modern Western replication. Not FDA-approved.
Selank
Russian regulatory approval but limited Western clinical validation. Most published human data is in Russian-language literature with limited English-language replication. The compound has a favorable safety profile in published studies but the evidence base is geographically concentrated. Not FDA-approved. Available through research peptide markets and specialty compounding, not standard Western clinical channels.
Best for
DSIP
- Research on endogenous sleep-regulatory peptides and delta-wave sleep promotion
- Research on HPA axis modulation and cortisol reduction through peptide-based approaches
- Research on the historical pharmacology of neuropeptides with observed effects but incomplete mechanistic characterization
Selank
- Research on anxiolytic mechanisms that avoid sedation and dependence pathways
- Research on tuftsin-derived peptides and their immunomodulatory plus anxiolytic dual activity
- Research comparing Russian-approved peptide therapeutics to Western anxiolytic standards
How to choose
A good fit for DSIP
- Research on endogenous sleep-regulatory peptides and delta-wave promotion
- Research on HPA axis modulation and cortisol reduction through peptide approaches
- Research on historical neuropeptide pharmacology with observed effects and incomplete mechanisms
A good fit for Selank
- Research on non-sedating anxiolytic mechanisms with well-characterized pathways
- Research contexts where regulatory approval and mechanistic clarity carry weight
- Research on GABAergic modulation that avoids benzodiazepine-type liabilities
Consider both across time
DSIP and Selank address related but distinct aspects of the stress-sleep-anxiety axis. DSIP targets sleep quality through delta-wave promotion and cortisol reduction. Selank targets waking anxiety through GABAergic modulation without causing sedation. For research on the intersection of sleep and anxiety, both compounds are relevant but from different angles. Selank has the clearer mechanism and regulatory validation; DSIP has documented sleep effects but with mechanistic questions that decades of research have not resolved.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Hypothalamic Action
- Hypothalamic Action promotes Delta-Wave Sleep Promotion
- Hypothalamic Action reduces Cortisol Reduction
- Delta-Wave Sleep Promotion connects to Sleep Quality Improvement
- Cortisol Reduction connects to Stress Response Reduction
- GABAergic Modulation
- GABAergic Modulation amplifies Enkephalin System Modulation
- GABAergic Modulation modulates Serotonin Metabolism Adjustment
- GABAergic Modulation increases BDNF Expression Increase
- Enkephalin System Modulation connects to Anxiety Reduction; Serotonin Metabolism Adjustment connects to Anxiety Reduction
- BDNF Expression Increase connects to Cognitive Support
DSIP acts on the hypothalamus to promote delta-wave sleep and reduce cortisol-driven stress responses.
Selank modulates GABAergic signaling and the enkephalin system to reduce anxiety without causing sedation or dependence.
Research Evidence
Selank has stronger evidence support: Russian regulatory approval with published human clinical studies. DSIP has multiple published human studies documenting sleep-promoting and stress-reducing effects, but primarily from 1980s-1990s research with limited modern replication. The mechanistic understanding gap for DSIP is the key differentiator: Selank's GABAergic pathway is well-characterized; DSIP's hypothalamic mechanism remains incomplete.
- 1.
For sleep quality specifically, DSIP has the more directly relevant mechanism.
- 2.
For anxiety that affects sleep, selank addresses the root cause (anxiety) rather than the symptom (poor sleep).
- 3.
For daytime anxiety without sedation, selank is the more appropriate compound.
- 4.
For circadian rhythm disruption, DSIP has specific research on sleep-wake regulation.
Key Limitations
- •No head-to-head comparison.
- •Both are Animal Studies with limited Western clinical data.
- •DSIP research is largely from the 1970s-1990s with limited replication.
- •Selank research is concentrated in Russian-language literature.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
DSIP
"DSIP gave me the best sleep of my life"
Plausible but limited human data
"DSIP is not a sleeping pill, it regulates sleep naturally"
Plausible distinction
Selank
"Selank eliminated my anxiety without the side effects of benzodiazepines"
Plausible but unproven
"Nasal spray is the best way to take it"
Supported by published data
"It stacks well with Semax for cognitive performance"
Anecdotal only
Safety Comparison
Both compounds have favorable safety profiles in published research. DSIP is an endogenous peptide the body naturally produces, providing biological plausibility for safety. Selank is non-sedating and non-addictive in published studies. Neither has long-term controlled safety data from Western clinical programs.
DSIP
Limited safety data. Research dates back to the 1970s. No serious adverse events in published studies. Not FDA-approved.
Selank
Approved in Russia for anxiety. Reported as well-tolerated with no dependence liability. Limited Western safety data.
What the Research Suggests
Different tools for different problems. DSIP for sleep. Selank for anxiety. If anxiety causes sleep problems, selank targets the root. If sleep is the primary issue regardless of anxiety, DSIP is more specific.